ArticleFrontiers in oncology2020
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial.Nature communications · 2026Article
- Akt inhibition enhances the antitumor efficacy of immune checkpoint blockades and radiotherapy in a syngeneic breast cancer model.Molecular therapy. Oncology · 2025Article
- Advanced hierarchical computational modeling-based rational development of platinum (II) nanocomplex to improve lung cancer therapy.Advanced functional materials · 2025Article
- Towards targeting the breast cancer immune microenvironment.Nature reviews. Cancer · 2024Review
- Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer.Cancers · 2024Review
- Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.Cancer letters · 2024Article
- Tumor microenvironment remodeling plus immunotherapy could be used in mesenchymal-like tumor with high tumor residual and drug resistant rate.Communications biology · 2023Article
- Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.International journal of molecular sciences · 2023Review
- Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.The oncologist · 2023Article
- Identification and verification of aging-related lncRNAs for prognosis prediction and immune microenvironment in patients with head and neck squamous carcinoma.Oncology research · 2023Article
- Metabolic Reprogramming Induces Macrophage Polarization in the Tumor Microenvironment.Frontiers in immunology · 2022Review
- Prognostic value of immune-related genes and comparative analysis of immune cell infiltration in lung adenocarcinoma: sex differences.Biology of sex differences · 2021Article
- PI3K inhibitors are finally coming of age.Nature reviews. Drug discovery · 2021Review
- Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in triple-negative breast cancer (TNBC) through miR-637/Akt1/β-catenin (cyclin D1) axis.Cell death & disease · 2021Article
- Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment.International journal of molecular sciences · 2021Review
- Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 1 country.
Douglas K MarksPerlmutter Cancer Center, NYU Langone Health, New York, NY, United States.
Robyn D GartrellDepartment of Pediatrics, Pediatric Hematology/Oncology and Medicine, Hematology/Oncology, Columbia University Irving Medical Center, New York, NY, United States.
Margueritta El AsmarBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Shuobo BoboilaHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Thomas HartCollege of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States.
Yan LuHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Qingfei PanDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, United States.
Jiyang YuDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, United States.
Hanina HibshooshHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Hua GuoWeill Cornell Medicine, New York Presbyterian Hospital, New York, NY, United States.
Eleni AndreopoulouDepartment of Surgery, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States.
Lisa WiechmannDepartment of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States.
Katherine CrewHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Joseph SparanoDivision of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, United States.
Dawn HershmanHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Eileen ConnollyDivision of Radiation Oncology, Columbia University Irving Medical Center, New York, NY, United States.
Yvonne SaengerHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Kevin KalinskyHerbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, United States.
Columbia University Irving Medical Center · USColumbia University · USAlbert Einstein College of Medicine · USSt. Jude Children's Research Hospital · USBloomberg (United States) · USCornell University · USMontefiore Medical Center · USNYU Langone Health · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MInstitutional Career Development CoreKL2TR001874 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GENKINGER, JEANINE M., SHIMBO, DAICHI · 2016 to 2025
$13.6MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MClinical and Translational Science AwardKL2TR000081 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$3.3MIntracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell DataR01GM134382 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YU, JIYANG · 2019 to 2023
$1.7MNCATS NIH HHS KL2 TR000081NCATS NIH HHS KL2 TR001874NCI NIH HHS P30 CA013696NCI NIH HHS UG1 CA189859NIGMS NIH HHS R01 GM134382
Abstract
PubMed holds no abstract for this paper.
Indexed as
AKT inhibitorbreast cancerMK-2206pre-surgicalquantitative multiplex immunofluorescencetumor immunobiologytumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.